Rutgers Recruiting Participants for Johnson & Johnson Phase 3 COVID-19 Vaccine Clinical Trial
November 19, 2020
November 19, 2020
NEW BRUNSWICK, New Jersey, Nov. 19 (TNSRes) -- Rutgers University issued the following news:
Rutgers University is a clinical trial site for the Janssen Pharmaceutical Companies of Johnson & Johnson's phase 3 clinical research study to evaluate the safety and efficacy of Janssen's COVID-19 vaccine candidate.
Rutgers will enroll as many as 2,000 participants from the university community and throughout New Jersey. Study participants who meet the eligibility requireme . . .
Rutgers University is a clinical trial site for the Janssen Pharmaceutical Companies of Johnson & Johnson's phase 3 clinical research study to evaluate the safety and efficacy of Janssen's COVID-19 vaccine candidate.
Rutgers will enroll as many as 2,000 participants from the university community and throughout New Jersey. Study participants who meet the eligibility requireme . . .